GLP-1 PEPTIDES

This class of research peptides is widely studied for their potential roles in weight regulation, appetite control, and type‑2 diabetes management. Many of these compounds are categorized as GLP‑1 receptor agonists, which function by activating Glucagon-Like Peptide-1 receptors — a mechanism linked to reduced appetite and improved insulin sensitivity.

However, newer-generation peptides go beyond GLP‑1 activation, targeting multiple pathways such as glucagon and amylin receptors, offering broader metabolic effects. Some emerging compounds do not act on GLP‑1 receptors at all, yet show promise in body weight and glucose regulation studies.

Our collection includes well-known GLP‑1 analogs and multi-agonist peptides like semaglutide, tirzepatide, and retatrutide, all available for laboratory and research use in New Zealand.